ArticleFrontiers in toxicology2026
Towards test guidelines and standards for advanced materials: scientific insights and recommendations from the MACRAMÉ project.
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Horizon Europe Project MACRAMÉ developed twelve recommendations towards Test Guidelines and Standards for safety assessment of advanced materials (AdMas) that capture the identified needs in characterisation and identification, safety testing, transformation and release as well as information flow along the AdMas lifecycle. MACRAMÉ highlights challenges posed by complex structures and transformations of AdMas and AdMas-enabled products for regulation and industry drawn on research on graphene-related materials, carbon nanotubes and poly(lactic-co-glycolic) acid in realistic use cases. MACRAMÉ translates advances in characterisation, transformation and release assessment, and New Approach Methodologies into actionable recommendations and calls on regulators, funding bodies, researchers and industry to develop and validate fit-for-purpose test methods, standards and guidance with the aim to enable safe and sustainable deployment of AdMas for societal challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.